Aventis Pharmaceuticals Inc.

Olivier Houille

Michael L Edwards

Frank Halley

Andrew David Morley

Herve Bouchard

Dominique Damour

Conception Nemecek

Tahir Nadeem Majid

Francois Clerc

Paul Joseph Cox

Charles J Gardner

Timothy A Gillespy

Shelley Amendola

Brian L Pedgrift

Dorothea Kominos

Christopher D Edlin

Chantal Carrez

Justine Yeun Quai Lai

Daniel N A Bezard

Kent W Neuenschwander

Julian Roy Levell

Stephanie Deprets

Mark Czekaj

Peter Charles Astles

Yong Gong

Guyan Liang

Paul R Eastwood

James R Pribish

Heinz Pauls

Stephanie D Deprets

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

Chemical compounds

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

Growing community of inventors

Magstatt-le-Bas, France

Olivier Houille